Nanomerics is a speciality pharmaceutical company which was spun out from University College London. Nanomerics creates differentiated medicines based on its patented Molecular Envelope Technology (MET).
Nascient Ltd is a funded, privately-held biotech company developing novel therapies for the treatment of inflammatory diseases.
Based in the United Kingdom, Nascient is developing Matriximab, a fully human mAb targeting the Fibrinogen Globe (FBG) of Tenascin C. FBG is a novel therapeutic target involved in the initiation of acute inflammation and the onset of chronic disease.
Nascient is funded by Imperial Innovations.